Article
Herbert Smith Freehills Kramer Comments For LSIPR On Small Molecule Litigation In The UPC
Life sciences-related cases started at a low level during the first years of the UPC's existence (about 25% of cases) and focused initially on the medtech sector.
Herbert Smith Freehills Kramer LLP